Loading...
01/10 16:48
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals strong financial performance with revenue exceeding expectations, positive guidance, and a new partnership. Despite competitive pressures, no significant negative impact was reported. The Q&A section highlights market share gains and no adverse effects from competitors. The increased revenue guidance and strong earnings, coupled with promising product development, suggest a positive stock price movement over the next two weeks.
US net product revenue $119.7 million (137% year-over-year growth, 16% sequential quarter-over-quarter growth) - This growth reflects strong demand for BRIUMVI.
Operating expenses Approximately $82 million (tracking slightly ahead of full year guidance of approximately $300 million) - The increase was primarily driven by about $20 million in manufacturing investments for subcutaneous BRIUMVI.
GAAP net income Approximately $5 million or $0.03 per diluted share - This positive result is attributed to the strong performance of BRIUMVI.
Cash, cash equivalents and investment securities $276 million - This positions the company strongly to continue executing its commercial strategy and advancing its pipeline.
BRIUMVI US net sales Q1 2025: BRIUMVI US net sales reached nearly $120 million in the first quarter, exceeding expectations.
New patient enrollment: The first three months of the year marked the highest months of total new patient enrollment since launch.
Subcutaneous BRIUMVI development: Development of a self-administered subcutaneous BRIUMVI is underway, with promising results from Phase 1 safety studies.
Streamlined treatment regimen: New data shows safety and tolerability of starting all patients on BRIUMVI with a single 600 mg dose on day one.
Market share growth: BRIUMVI is gaining dynamic market share in the anti-CD20 IV segment, driven by newly diagnosed patients and switch patients.
Revenue guidance increase: Full-year 2025 US net revenue guidance raised from $525 million to $560 million.
Operating expenses Q1 2025: Total operating expenses for the quarter were approximately $82 million, tracking ahead of full-year guidance.
Manufacturing investments: About $20 million in manufacturing investments for subcutaneous BRIUMVI were made during the quarter.
Direct-to-patient advertising: Launching the first direct-to-patient BRIUMVI television commercial campaign to educate and activate patients.
Expansion into new indications: Exploring potential for subcutaneous BRIUMVI in Myasthenia Gravis and other indications.
Competitive Pressures: Despite strong sales growth, BRIUMVI operates in a highly competitive market with ongoing product launches from competitors.
Regulatory Issues: Potential tariffs on imported goods, including BRIUMVI manufactured in South Korea, are being monitored, although they are not expected to materially impact gross margins.
Supply Chain Challenges: The company is investing approximately $20 million in manufacturing for subcutaneous BRIUMVI, indicating potential supply chain challenges.
Economic Factors: The company is closely watching economic developments that could affect operations, including tariffs.
BRIUMVI US net sales Q1 2025: BRIUMVI US net sales reached nearly $120 million in the first quarter, exceeding expectations.
Growth Strategy: TG Therapeutics aims to make BRIUMVI the number one prescribed anti-CD20 therapy by increasing adoption among healthcare providers.
Subcutaneous BRIUMVI Development: Development of a self-administered subcutaneous BRIUMVI is underway, with promising results from Phase 1 safety studies.
Azer-cel Development: TG is advancing azer-cel, an allogeneic CD19 CAR-T cell therapy, into Phase 1 trials for progressive forms of MS.
Full-year 2025 US net revenue guidance: Increased from $525 million to $560 million based on strong Q1 performance.
Q2 2025 revenue target: Targeting $135 million for the second quarter.
Operating expenses guidance: Full-year operating expenses expected to be approximately $300 million.
GAAP net income Q1 2025: Reported GAAP net income of approximately $5 million or $0.03 per diluted share.
Share Repurchase Program: None
The earnings call summary highlights strong financial performance with significant growth in revenue and net income. The company's strategic initiatives, like the development of subcutaneous BRIUMVI and market expansion efforts, are promising. The Q&A section reveals optimism about future growth, despite some uncertainties in competitive dynamics and lack of specific guidance for 2026. The raised revenue guidance and strong market share growth for BRIUMVI further support a positive outlook. Overall, these factors suggest a likely positive stock price movement in the short term.
The earnings call reveals strong financial performance with increased revenue, exceeding expectations, and robust growth in BRIUMVI sales. The company raised its full-year revenue guidance, indicating confidence in future performance. Despite increased OpEx, profitability remains strong. The Q&A section highlights positive growth trends and strategic development plans, though some concerns about competition and market dynamics persist. Overall, the positive financial metrics, raised guidance, and strategic initiatives suggest a likely positive stock price reaction in the short term.
The earnings call reveals strong financial performance with revenue exceeding expectations, positive guidance, and a new partnership. Despite competitive pressures, no significant negative impact was reported. The Q&A section highlights market share gains and no adverse effects from competitors. The increased revenue guidance and strong earnings, coupled with promising product development, suggest a positive stock price movement over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
